Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avelumab - Merck KGaA

Next Previous
X
Search
Drug Profile

Avelumab - Merck KGaA

Alternative Names: Anti-CD274-monoclonal-antibody; Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck KGaA; BAVENCIO; MSB-0010718C; PF-06834635

Latest Information Update: 02 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck Biopharma; Merck KGaA
  • Developer 4SC; AIO Studien gGmbH; Array BioPharma; Baylor College of Medicine; Chong Kun Dang; Dana-Farber Cancer Institute; Debiopharm; eFFECTOR Therapeutics; EMD Serono; Forty Seven; Fred Hutchinson Cancer Research Center; G1 Therapeutics; Gachon University Gil Medical Center; Hellenic Cooperative Oncology Group; Hoosier Cancer Research Network; Hospices Civils de Lyon; Istituto Oncologico Veneto; Johannes Gutenberg-University Mainz; M. D. Anderson Cancer Center; Merck Biopharma; Merck KGaA; National Cancer Institute (USA); Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Transgene; University College London; University of Birmingham; University of California, San Diego; University of Iowa; University of North Carolina at Chapel Hill; University of Padua; Vaccinex; Vanderbilt-Ingram Cancer Center; VAXIMM; Verastem Oncology; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma; Renal cell carcinoma; Urogenital cancer
  • Phase III Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
  • Phase II Bladder cancer; Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Gestational trophoblastic disease; Glioblastoma; Haemangiosarcoma; HER2 negative breast cancer; HER2 positive breast cancer; Hodgkin's disease; Intestinal cancer; Leiomyosarcoma; Liver cancer; Lymphoma; Malignant thymoma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Osteosarcoma; Penile cancer; Peripheral T-cell lymphoma; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Small cell lung cancer; Squamous cell cancer; Testicular cancer; Thymoma
  • Phase I/II Anal cancer; Bone metastases; Cervical cancer; Liposarcoma; Oropharyngeal cancer; Pancreatic cancer; Vulvovaginal cancer
  • Phase I CNS cancer; Follicular lymphoma
  • No development reported Acute myeloid leukaemia; Meningioma

Most Recent Events

  • 28 Jun 2024 Efficacy data from the phase III A-BRAVE trial in Triple-negative-breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 26 Jun 2024 Pfizer completes the phase III JAVELIN Renal 101 trial in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in USA, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Mexico, the Netherlands, New Zealand, Romania, Russia, South Korea, Spain, Sweden and the UK. (IV) (NCT02684006)
  • 24 Jun 2024 EMD Serono terminates a phase I/II trial in Solid tumours and Lymphoma (Second-line therapy or greater, In adolescents, In children, In infants, In neonates) in Belgium, Canada, Denmark, South Korea, USA based on the limited activity observed with avelumab monotherapy (NCT03451825)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top